Plus Therapeutics To Report Second Quarter Fiscal Year 2020 Financial Results And Corporate Update on August 10, 2020
August 03 2020 - 7:00AM
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today
announced that it will report its Second Quarter Fiscal Year 2020
financial results after the close of market on August 10, 2020. The
company plans to hold a conference call and live audio webcast at
5:00 PM Eastern Time to discuss its financial results and provide a
general business update.
Event: |
Plus Therapeutics Second Quarter Fiscal Year 2020 Financial Results
Conference Call and Webcast. |
Date: |
Monday, August 10, 2020. |
Time: |
5:00 PM Eastern Time. |
Live Call: |
Phone Number: (877) 402-3914;
Conference ID: 5925129 |
Live Webcast: |
https://event.on24.com/wcc/r/2402905/A6C80D40192BA72B1FDF935FEAFD7277Beginning
two hours after the conclusion of the conference call, a replay
will be available. |
Replay: |
http://ir.plustherapeutics.com/events/default.aspx |
About Plus Therapeutics, Inc.
Plus Therapeutics (Nasdaq: PSTV) is a
clinical-stage pharmaceutical company whose radiotherapeutic
portfolio is concentrated on nanoliposome-encapsulated
radionucleotides for several cancer targets. Central to the
Company’s drug development is a unique nanotechnology platform
designed to reformulate, deliver and commercialize multiple drugs
targeting rare cancers and other diseases. The platform is designed
to facilitate new delivery approaches and/or formulations of safe
and effective, injectable drugs, potentially enhancing the safety,
efficacy and convenience for patients and healthcare providers.
More information may be found at www.plustherapeutics.com and
www.respect-trials.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains certain statements
that may be deemed “forward-looking statements” within the meaning
of U.S. securities laws. All statements, other than statements of
historical fact, that address activities, events or developments
that we intend, expect, project, believe or anticipate and similar
expressions or future conditional verbs such as will, should,
would, could or may occur in the future are forward-looking
statements. Such statements are based upon certain assumptions and
assessments made by our management in light of their experience and
their perception of historical trends, current conditions, expected
future developments and other factors they believe to be
appropriate. These statements include, without limitation,
statements about: the Company’s potential to facilitate new
delivery approaches and/or formulations of safe and effective,
injectable drugs, potentially enhancing the safety, efficacy and
convenience for patients and healthcare providers; the Company’s
potential to develop drug candidates currently in its product
pipeline; and the Company’s potential to develop additional drugs
outside of its current pipeline. The forward-looking statements
included in this press release are subject to a number of
additional material risks and uncertainties, including but not
limited to: the risk that the Company is not able to successfully
develop product candidates that can leverage the U.S. FDA’s
accelerated regulatory pathways; and the risks described under the
heading “Risk Factors” in the Company’s Securities and Exchange
Commission filings, including in the Company’s annual and quarterly
reports. There may be events in the future that the Company is
unable to predict, or over which it has no control, and its
business, financial condition, results of operations and prospects
may change in the future. The Company assumes no responsibility to
update or revise any forward-looking statements to reflect events,
trends or circumstances after the date they are made unless the
Company has an obligation under U.S. federal securities laws to do
so.
Contact:Plus Therapeutics,
Inc. Andrew Sims VP – Chief Financial Officer,
Investor Relations Phone: +1.619.333.4150
Email: ir@plustherapeutics.com
Website: plustherapeutics.comClinical Website:
respect-trials.com
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Apr 2023 to Apr 2024